Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 7, 2010, Pages 1291-1299

  Yang, Wenfeng ^a   Zhang, Yongming ^a   Fu, Zheng ^a   Yu, Jinming ^a   Sun, Xiaorong ^a   Mu, Dianbin ^a   Han, Anqin ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

18F FDG PET CT; 18F FLT PET CT; Cyclin D1; Non small cell lung cancer

Indexed keywords

3' FLUOROTHYMIDINE F 18; CYCLIN D1; FLUORODEOXYGLUCOSE F 18; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MOLECULAR IMAGING; SENSITIVITY AND SPECIFICITY; TUMOR CELL; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; TRANSPORT AT THE CELLULAR LEVEL;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYCLIN D1; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77954959768     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1412-6     Document Type: Article

References (39)

1. Yamamoto Y, Nishiyama Y, Monden T, et al. Correlation of FDG-PET findings with histopathology in the assessment of response to induction chemoradiotherapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2006;33:140-7.
2. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-9.
3. Yang W, Fu Z, Yu J, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 2008;61:35-43.
4. Mier W, Haberkorn U, Eisenhut M. [18F]FLT: portrait of a proliferation marker. Eur J Nucl Med 2002;29:165-9.
5. Martin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-25.
6. Au NH, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204:101-9.
7. Saitoh G, Sugio K, Ishida T, et al. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. Oncol Rep 2001;8:737-43.
8. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. Lung Cancer 2001;34:207-18.
9. Oshita F, Ito H, Ikehara M, et al. Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. Am J Clin Oncol 2004;27:425-8.
10. Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[(18) F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
11. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′ deoxy-3′-[(18) F]fluorothymidine ([(18) F]FLT) as a proliferation imaging tracer in humans: correlation of [(18) F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23.
12. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14. (Pubitemid 47357522)
13. Yamamoto Y, Nishiyama Y, Kimura N, et al. Comparison of (18) F-FLT PET and (18) F-FDG PET for preoperative staging in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2008;35:236-45.
14. Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med 2008;49:186-94.
15. Marom EM, Aloia TA, Moore MB, et al. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer 2001;33:99-107.
16. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
17. Schwartz JL, Tamura Y, Jordan R, et al. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymi-dine and thymidine analogs. J Nucl Med 2003;44:2027-32.
18. Dimitrakopoulou-Strauss A, Strauss LG. The role of 18F-FLT in cancer imaging: does it really reflect proliferation? Eur J Nucl Med Mol Imaging 2008;35:523-6.
19. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10.
20. Reske SN, Deisenhofer S. Is 3′-deoxy-3′-(18) F-fluorothymidine a better marker for tumour response than (18) F-fluorodeoxyglu-cose? Eur J Nucl Med Mol Imaging 2006;33 Suppl 1:38-43.
21. Wieder HA, Geinitz H, Rosenberg R, et al. PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 2007;34:878-83.
22. Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 2006;129:393-401.
23. Troost EG, Vogel WV, Merkx MA, et al. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007;48:726-35.
24. Kato JY, Matsuoka M, Strom DK, et al. Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. Mol Cell Biol 1994;4:2713-21.
25. Gautschi O, Ratschiller D, Gugger M, et al. Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung Cancer 2007;55:1-14.
26. Ratschiller D, Heighway J, Gugger M, et al. Cyclin D1 over-expression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003;21:2085-93.
27. Benzeno S, Lu F, Guo M, et al. Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene 2006;25:6291-303.
28. Soomro IN, Holmes J, Whimster WF. Predicting prognosis in lung cancer: use of proliferation marker, Ki67 monoclonal antibody. J Pak Med Assoc 1998;48:66-9.
29. Zhou P, Jiang W, Zhang YJ, et al. Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 1995;11:571-80.
30. Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD-0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004;3:1427-38.
31. Leyton J, Smith G, Lees M, et al. Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901. Mol Cancer Ther 2008;7:3112-21.
32. Arnér ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther 1995;67:155-86.
33. Hoffman EJ, Huang SC, Phelps ME. Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979;3:299-308.
34. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med 2007;48:932-45.
35. Rousset O, Rahmim A, Alavi A, et al. Partial volume correction strategies in PET. PET Clinics 2007;2:235-49.
36. Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy- D-glucose-positron emission tomography/computed to-mography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97-106.
37. Hickeson M, Yun M, Matthies A, et al. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging 2002;29:1639-47.
38. Vesselle H, Schmidt RA, Pugsley JM, et al. Lung cancer proliferation correlates with F-18 fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-44.
39. Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 2005;46:424-8.